Department of Endocrinology and Metabolic Diseases, Centre Hospitalier Universitaire Larrey, Toulouse Cedex, France.
Clin Endocrinol (Oxf). 2011 Jun;74(6):694-8. doi: 10.1111/j.1365-2265.2011.04021.x.
Some patients with parathyroid carcinoma present with an over-production of nontruncated amino-terminal (NT-N) parathyroid hormone (PTH), a post-transcriptionally modified form of PTH(1-84). This is usually picked up on an elevated whole (W) PTH (third-generation)/total (T) (second-generation) PTH assay ratio (N > 0·8).
Two parathyroid cancer patients with several episodes of hypercalcaemia and multiple surgeries are described. In both patients, W-PTH, T-PTH and circulating PTH molecular forms separated by high-pressure liquid chromatography (HPLC) were measured with the same assays. qPCR was used to study HRPT2 gene mutation.
The first patient had total calcium of 3·8 and 3·22 mmol/l before the fourth and fifth surgeries, and third/second-generation PTH ratios of 2·95 and 3·6, respectively. After the fourth surgery, the ratio remained normal for 1 year and increased progressively to 3·6 over 15 months. This preceded hypercalcaemia by 6 months. The ratio became normal after the fifth surgery. HPLC analysis disclosed an over-expression of NT-N PTH to 82·2% (N < 10%) relative to hPTH(1-84) before the fifth surgery. A deletion of all the tested exons of the HRPT2 gene was identified. In the second patient, W-PTH/T-PTH ratio was 0·89 when serum calcium was 3·3 mmol/l. NT-N PTH was also over-expressed at 51·9%. An inactivating mutation of the HRPT2 gene was also identified.
This may suggest that a progressive rise in third/second-generation ratio may have possible clinical utility to monitor parathyroid cancer recurrence. A possible association between NT-N PTH overproduction and HRPT2 gene inactivation is also suggested.
甲状旁腺癌患者可出现无截短的氨基端(NT-N)甲状旁腺激素(PTH)过度产生,这是 PTH(1-84)的转录后修饰形式。这通常可通过升高的全(W)PTH(第三代)/总(T)(第二代)PTH 检测比值(N>0·8)发现。
我们描述了 2 例甲状旁腺癌患者,他们经历了多次高钙血症和多次手术。在这 2 例患者中,均采用相同的检测方法测量 W-PTH、T-PTH 和经高压液相色谱(HPLC)分离的循环 PTH 分子形式。使用 qPCR 研究 HRPT2 基因突变。
第 1 例患者在第 4 次和第 5 次手术前血钙分别为 3·8 和 3·22mmol/L,第 3/2 代 PTH 比值分别为 2·95 和 3·6。第 4 次手术后,该比值在 1 年内保持正常,在 15 个月内逐渐升高至 3·6,早于高钙血症 6 个月。第 5 次手术后该比值恢复正常。HPLC 分析显示,在第 5 次手术前,NT-N PTH 相对 hPTH(1-84)过度表达 82·2%(N<10%)。检测到 HRPT2 基因的所有外显子均缺失。第 2 例患者血钙为 3·3mmol/L 时,W-PTH/T-PTH 比值为 0·89。NT-N PTH 也过度表达,为 51·9%。还鉴定出 HRPT2 基因的失活突变。
这表明第三代/第二代比值的逐渐升高可能对监测甲状旁腺癌复发具有潜在的临床应用价值。还提示 NT-N PTH 过度产生与 HRPT2 基因突变失活之间可能存在关联。